Want to see DGX full AI Analyst Report?
DGX Stock Chart & Stats
$195.02
-$0.03(-0.02%)
At close: 4:00 PM EST
$195.02
-$0.03(-0.02%)
Day’s Range― - ―
52-Week Range$164.65 - $219.20
Previous CloseN/A
Volume143.08K
Average Volume (3M)804.82K
Market Cap
$22.96B
Enterprise Value$28.48B
Total Cash (Recent Filing)$393.00M
Total Debt (Recent Filing)$6.98B
Price to Earnings (P/E)22.6
Beta0.06
Next Earnings
Jul 23, 2026EPS Estimate
2.83Next Dividend Ex-DateN/A
Dividend Yield1.8%
Share Statistics
EPS (TTM)9.17
Shares Outstanding110,696,430
10 Day Avg. Volume723,516
30 Day Avg. Volume804,818
Financial Highlights & Ratios
PEG Ratio1.43
Price to Book (P/B)2.69
Price to Sales (P/S)1.75
P/FCF Ratio14.17
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue2.53
Enterprise Value/Gross Profit7.60
Enterprise Value/Ebitda13.41
Forecast
1Y Price Target
$226.50Price Target Upside16.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)10.75
Revenue Forecast (FY)$11.86B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue & Volume GrowthConsistent double-digit organic revenue and requisition growth demonstrates durable demand and effective commercial execution. Volume gains, supported by Corewell and Fresenius collaborations and stronger consumer channels, create predictable specimen flow and underpin revenue visibility and guide upgrades over the next several quarters.
Higher-value Advanced DiagnosticsRapid growth in esoteric and specialty tests shifts mix toward higher-margin services and benefits long-term revenue per requisition. Structural drivers (new guidelines, disease awareness) and investments in capacity increase stickiness with providers and payers, supporting margin resilience beyond routine testing cycles.
Productivity Via AI, Automation & Cost ProgramsMeaningful productivity gains from AI and automation lower unit costs and improve operating leverage over time. Combined with an ongoing Invigorate cost program, these structural efficiency improvements enhance margin expansion potential and competitiveness while supporting scalable growth in patient volumes and DTC engagement.
Bears Say
Meaningful Leverage RemainsDebt near parity with equity restricts strategic flexibility and increases vulnerability to rate or reimbursement shocks. Although leverage has improved from 2024, ongoing debt obligations limit capital allocation to M&A, buybacks or faster capex, and raise refinancing and interest-cost sensitivity over the medium term.
Mix-driven Revenue-per-Requisition PressureLarge collaboration ramps are increasing volume but shifting mix toward lower-priced routine tests, compressing revenue per requisition. As these partnerships scale, structural mix effects can cap pricing power and slow margin expansion, requiring either higher esoteric growth or efficiency gains to offset.
Medicare/PAMA & Regulatory UncertaintyFuture Medicare pricing and industry-level CMS/OIG scrutiny create durable policy risk that could reduce reimbursement or raise compliance costs. Given reliance on third‑party payers, adverse PAMA outcomes or regulatory enforcement would materially pressure revenue and margins across the lab industry for multiple years.
Quest Diagnostics News
DGX FAQ
What was Quest Diagnostics’s price range in the past 12 months?
Quest Diagnostics lowest stock price was $164.65 and its highest was $219.20 in the past 12 months.
What is Quest Diagnostics’s market cap?
Quest Diagnostics’s market cap is $22.96B.
When is Quest Diagnostics’s upcoming earnings report date?
Quest Diagnostics’s upcoming earnings report date is Jul 23, 2026 which is in 10 days.
How were Quest Diagnostics’s earnings last quarter?
Quest Diagnostics released its earnings results on Apr 21, 2026. The company reported $2.5 earnings per share for the quarter, beating the consensus estimate of $2.366 by $0.134.
Is Quest Diagnostics overvalued?
According to Wall Street analysts Quest Diagnostics’s price is currently Undervalued.
Does Quest Diagnostics pay dividends?
Quest Diagnostics pays a Quarterly dividend of $0.86 which represents an annual dividend yield of 1.8%. See more information on Quest Diagnostics dividends here
What is Quest Diagnostics’s EPS estimate?
Quest Diagnostics’s EPS estimate is 2.83.
How many shares outstanding does Quest Diagnostics have?
Quest Diagnostics has 110,696,430 shares outstanding.
What happened to Quest Diagnostics’s price movement after its last earnings report?
Quest Diagnostics reported an EPS of $2.5 in its last earnings report, beating expectations of $2.366. Following the earnings report the stock price went up 4.447%.
Which hedge fund is a major shareholder of Quest Diagnostics?
Currently, no hedge funds are holding shares in DGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Quest Diagnostics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$226.50 (16.14% Upside)
$226.50 (16.14% Upside)
Blogger Sentiment
Bullish
DGX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 798.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 14.0%
Last 30 Days ▲ 14.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.11%
12-Months-Change
Fundamentals
Return on Equity
14.11%
Trailing 12-Months
Asset Growth
5.55%
Trailing 12-Months
Company Description
Quest Diagnostics
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
DGX Revenue Breakdown
97.73% Diagnostic Information Services
2.27% DS businesses
DGX Stock 12 Month Forecast
Average Price Target
$226.50
▲(16.14% Upside)
Technical Analysis
Ownership Overview
0.46% Insiders
28.63% Mutual Funds
0.48% Other Institutional Investors
41.91% Public Companies and
Individual Investors